BACKGROUND: Lenalidomide is approved for the treatment of anemia with transfusion dependence (TD) in patients with lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del5q-MDS), but its "real-life" use and effect on transfusion needs are unclear. In the current study, the authors examined its use in the Medicare population. METHODS: Patients with MDS who were enrolled in Medicare Parts A, B, and D were identified using International Classification of Diseases 9-Clinical Modification (ICD-9) codes from 100% Medicare claims from 2006 through 2008. Patients were followed until the end of the study or death. Claims were used to determine time to initiation of lenalidomide, daily dose, duration, and other MDS therapies. Transfusion status was defined each week based on transfusion use in rolling 8-week period: TD, required transfusions during 2 weeks, separated by ≥ 3 weeks; transfusion user (TU), 1 transfusion; and transfusion independence (TI), no transfusions. RESULTS: A total of 753 of 23,855 patients (3.2%) received lenalidomide, including 31% of 470 patients with del5q-MDS. At the time of lenalidomide initiation, 33% of patients were TD, 31% were TU, and 36% were TI. The median time to lenalidomide initiation was shorter for patients with del5q-MDS than for other lower-risk patients (8 weeks vs 20 weeks; P < .01). The percentage of patients with del5q-MDS receiving lenalidomide increased over time. Lenalidomide initiation was found to be negatively associated with older age and baseline diabetes, stroke, and renal disease. During the observation period, 44% of TU/TD patients (53% of the patients with del5q-MDS) achieved reductions in transfusion use; among TD patients receiving ≥ 3 cycles, 77% reduced their transfusion use and 40% achieved TI. CONCLUSIONS: To the authors' knowledge, the current study is the first report of lenalidomide use in a large Medicare-enrolled population with MDS. Reductions in transfusion rates were overall consistent with data from clinical trials. Response rates were higher when ≥ 3 lenalidomide cycles were received.
BACKGROUND:Lenalidomide is approved for the treatment of anemia with transfusion dependence (TD) in patients with lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del5q-MDS), but its "real-life" use and effect on transfusion needs are unclear. In the current study, the authors examined its use in the Medicare population. METHODS:Patients with MDS who were enrolled in Medicare Parts A, B, and D were identified using International Classification of Diseases 9-Clinical Modification (ICD-9) codes from 100% Medicare claims from 2006 through 2008. Patients were followed until the end of the study or death. Claims were used to determine time to initiation of lenalidomide, daily dose, duration, and other MDS therapies. Transfusion status was defined each week based on transfusion use in rolling 8-week period: TD, required transfusions during 2 weeks, separated by ≥ 3 weeks; transfusion user (TU), 1 transfusion; and transfusion independence (TI), no transfusions. RESULTS: A total of 753 of 23,855 patients (3.2%) received lenalidomide, including 31% of 470 patients with del5q-MDS. At the time of lenalidomide initiation, 33% of patients were TD, 31% were TU, and 36% were TI. The median time to lenalidomide initiation was shorter for patients with del5q-MDS than for other lower-risk patients (8 weeks vs 20 weeks; P < .01). The percentage of patients with del5q-MDS receiving lenalidomide increased over time. Lenalidomide initiation was found to be negatively associated with older age and baseline diabetes, stroke, and renal disease. During the observation period, 44% of TU/TD patients (53% of the patients with del5q-MDS) achieved reductions in transfusion use; among TD patients receiving ≥ 3 cycles, 77% reduced their transfusion use and 40% achieved TI. CONCLUSIONS: To the authors' knowledge, the current study is the first report of lenalidomide use in a large Medicare-enrolled population with MDS. Reductions in transfusion rates were overall consistent with data from clinical trials. Response rates were higher when ≥ 3 lenalidomide cycles were received.
Authors: B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg Journal: Blood Date: 2000-12-01 Impact factor: 22.113
Authors: Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey Journal: Health Aff (Millwood) Date: 2006 Sep-Oct Impact factor: 6.301
Authors: Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Carlos M De Castro; H Joachim Deeg; James M Foran; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Stephen D Nimer; Margaret R O'Donnell; Mark A Schroeder; Paul J Shami; Richard M Stone; James E Thompson; Peter Westervelt Journal: J Natl Compr Canc Netw Date: 2011-01 Impact factor: 11.908
Authors: Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Amy J Davidoff; Ilene H Zuckerman; Naimish Pandya; Franklin Hendrick; Xuehua Ke; Arti Hurria; Stuart M Lichtman; Arif Hussain; Jonathan P Weiner; Martin J Edelman Journal: J Geriatr Oncol Date: 2013-04 Impact factor: 3.599
Authors: Mikkael A Sekeres; W Marieke Schoonen; Hagop Kantarjian; Alan List; Jon Fryzek; Ronald Paquette; Jaroslaw P Maciejewski Journal: J Natl Cancer Inst Date: 2008-10-28 Impact factor: 13.506
Authors: Lionel Adès; Simone Boehrer; Thomas Prebet; Odile Beyne-Rauzy; Laurence Legros; Christophe Ravoet; François Dreyfus; Aspasia Stamatoullas; Marie Pierre Chaury; Jacques Delaunay; Guy Laurent; Norbert Vey; Sara Burcheri; Rose-Marie Mbida; Natacha Hoarau; Claude Gardin; Pierre Fenaux Journal: Blood Date: 2008-11-05 Impact factor: 22.113
Authors: Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List Journal: Blood Date: 2007-09-24 Impact factor: 22.113
Authors: Dana P Goldman; Anupam B Jena; Darius N Lakdawalla; Jennifer L Malin; Jesse D Malkin; Eric Sun Journal: Health Serv Res Date: 2009-10-29 Impact factor: 3.402
Authors: Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff Journal: J Comp Eff Res Date: 2015-08 Impact factor: 1.744
Authors: A M Zeidan; M A Sekeres; G Garcia-Manero; D P Steensma; K Zell; J Barnard; N A Ali; C Zimmerman; G Roboz; A DeZern; A Nazha; E Jabbour; H Kantarjian; S D Gore; J P Maciejewski; A List; R Komrokji Journal: Leukemia Date: 2015-10-14 Impact factor: 11.528
Authors: Amer M Zeidan; Rong Wang; Xiaoyi Wang; Rory M Shallis; Nikolai A Podoltsev; Jan P Bewersdorf; Scott F Huntington; Natalia Neparidze; Smith Giri; Steven D Gore; Amy J Davidoff; Xiaomei Ma Journal: Blood Adv Date: 2020-05-26
Authors: Aleksandra Butrym; Ewa Lech-Maranda; Elżbieta Patkowska; Beata Kumiega; Maria Bieniaszewska; Andrzej Mital; Krzysztof Madry; Tigran Torosian; Ryszard Wichary; Justyna Rybka; Krzysztof Warzocha; Grzegorz Mazur Journal: BMC Cancer Date: 2015-07-08 Impact factor: 4.430
Authors: Amer M Zeidan; Jessica B Long; Rong Wang; Xin Hu; James B Yu; Scott F Huntington; Gregory A Abel; Sarah S Mougalian; Nikolai A Podoltsev; Steven D Gore; Cary P Gross; Xiaomei Ma; Amy J Davidoff Journal: PLoS One Date: 2017-09-13 Impact factor: 3.240